Home

Connect with the community

CORA 2025 will take place in Venice, Italy from 6-8 March 2025 and is an excellent forum to discuss the controversies in rheumatology & autoimmunity. Ongoing debate among professionals on the topics of treatment, diagnosis, and translating research into practice is essential for addressing these controversies and advancing knowledge in the field.

Why Attend

Inspire your tomorrow: the transformative benefits of attending CORA 2025

[mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Be the first to witness groundbreaking research in rheumatology and autoimmunity at CORA 2025.[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Engage in thought-provoking debates on key controversies in rheumatology and autoimmunity.[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Meet key opinion laders and gain insights that can advance your career.[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Connect with colleagues and build lasting professional relationships.[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Showcase your expertise, present your research, and gain recognition in the field.[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]

Earn up to 15 CME credits and advance your career with expert insights and takeaways.

[/mvc_infobox][mvc_infobox info_style=”mega_info_box_2″ info_opt=”show_icon” icon_size=”24″ title_color=”#ffffff” font_icon=”fas fa-arrow-alt-circle-right” icon_color=”#bcd75e” icon_bg=”#ffffff”]Discover the latest industry innovations and advancements in rheumatic and autoimmune treatments.[/mvc_infobox]

Inspire your tomorrow: the transformative benefits of attending CORA 2025

  • Get the best out of the debates on controversies in rheumatology and autoimmunity
  • Be the first to witness new scientific findings
  • Meet key opinion leaders
  • Showcase your research and expertise
  • Explore the industry innovations
  • Network with colleagues

Register Today

Join the conversation

Download the App

Elevate your congress experience

Earn up to 15 CME Credits

Expand your knowledge

CORA 2025 Highlights

Debate 3
LN Treatment: Early Combination
vs. Standard Treatment

Ioannis Parodis,
Sweden

 

EARLY COMBINATION

Laurent Arnaud,
France

 

STANDARD TREATMENT

Debate 21
Transition From Psoriasis to Psoriatic Arthritis:
Are We Getting Closer?

Alen Zabotti,
Italy

 

YES

Dennis McGonagle,
UK

 

NO

Venice will enchant you

Maximize both your professional and personal experience. Dive into groundbreaking research and debate the latest advancements at the 8th International Congress on Controversies in Rheumatology & Autoimmunity. After a busy Congress day, unwind by exploring Venice—stroll through St. Mark's Square, take a magical gondola ride, savor traditional cuisine, and soak in the vibrant atmosphere of this incredible city.

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

CORA 2025 Debates

Explore all 21 debates. Join us and voice your opinion.
Debate 1

March 6, 2025, 13:00-14:00 (CET)

What Should We Use As the First-Line Treatment for RA?

b/tsDMARDs: Zoltan Szekanecz
MTX: Andrea Rubbert-Roth
Debate 2

March 6, 2025, 13:00-14:00 (CET)

Are the New Classification Criteria a Step Forward in the Management of Antiphospholipid Syndrome?

Yes: Savino Sciascia
No: Jaume Alijotas-Reig
Debate 3

March 6, 2025, 14:10-15:10 (CET)

LN Treatment: Early Combination vs. Standard Treatment

Early Combination: Ioannis Parodis
Standard Treatment: Laurent Arnaud
Debate 4

March 6, 2025, 14:10-15:10 (CET)

The Use of Medical Cannabis in Rheumatic Pain Management: Valid Option or Unproven treatment?

Valid Option: Howard Amital
Unproven Treatment: Winfried Häuser
Debate 5

March 7, 2025, 9:05-10:05 (CET)

Beyond Physical Examination – How to Approach to RA Management: Joint Ultrasound or Synovial Biopsy?

Joint Ultrasound: Maria-Antonietta D'Agostino
Synovial Biopsy: Felice Rivellese
Debate 6

March 7, 2025, 9:05-10:05 (CET)

Mepolizumab in EGPA: Does One Size Fit All?

Yes: Benjamin Terrier
No: Giacomo Emmi
Debate 7

March 7, 2025, 10:45-11:45 (CET)

TNFi or IL17i for the Slowing the Radiographic Progression in Spondyloarthritis?

TNFi: Mikkel Østergaard
IL17i: Salvatore D'Angelo
Debate 8

March 7, 2025, 10:45-11:45 (CET)

Gut Microbiome in Rheumatic Diseases: Revolutionary or Fake News?

Revolutionary: Francesco Ciccia
Fake News: Zoltan Szekanecz
Debate 9

March 7, 2025, 11:50-12:50 (CET)

CAR-T Cells in Rheumatic Diseases: Game-Changer or Just a Buzz?

Game-Changer: Laura Bucci
Just a Buzz: Marit Stockfelt
Debate 10

March 7, 2025, 11:50-12:50 (CET)

Is Seronegative Sjogren Syndrome a Distinct Clinical Entity? & Should Hydroxychloroquine Be Used in Patients With Sjogren Syndrome?

Yes: Roberto Gerli
No: Athanasios Tzioufas
Debate 11

March 7, 2025, 15:10-16:10 (CET)

Early Biologic Treatment in Systemic Lupus: Necessary or Overemphasized?

Necessary: Mariele Gatto
Overemphasized: Chris Wincup
Debate 12

March 7, 2025, 15:10-16:10 (CET)

Is Hematopoietic Stem Cell Transplantation (Really) a Valid Option for Patients With Systemic Sclerosis?

Yes: Dominique Farge
No: Oliver Distler
Debate 13

March 7, 2025, 16:50-17:50 (CET)

Can We Give Targeted Therapies in Patients With Cancer?

Yes: Eden Sebbag
No: Zoltan Szekanecz
Debate 14

March 7, 2025, 16:50-17:50 (CET)

Are IPAF and UCTD Two Clinical Variants of the Same Systemic Autoimmune Disorder?

Two Clinical Variants: Marco Sebastiani
The Same: Szilvia Szamosi
Debate 15

March 7, 2025, 17:55-18:55 (CET)

Do JAK Inhibitors Aggravate Comorbidities Such As Cardiovascular Disease and Cancer?

Yes: Serena Bugatti
No: Ernest Choy
Debate 16

March 8, 2025, 9:00-10:00 (CET)

Should We Treat preRA/at Risk RA Individuals or Not?

Yes: Andrew Cope
No: György Nagy
Debate 17

March 8, 2025, 9:00-10:00 (CET)

Is It Common To Achieve the T2T Goals in SLE Patients?

Yes: Marta Mosca
No: Anisur Rahman
Debate 18

March 8, 2025, 11:10-12:10 (CET)

Axial Psoriatic Arthritis and axSpA: To Lump or to Split

To Lump: Philippe Sewerin
To Split: Ennio Lubrano
Debate 19

March 8, 2025, 11:10-12:10 (CET)

Should Immunosuppressive Drugs Be Used in All Patients With the Limited Cutaneous Form of SSc?

Yes: Marco Matucci-Cerinic
No: Yannick Allanore
Debate 20

March 8, 2025, 14:30-15:30 (CET)

Is It Safe to Use Low-Dose Glucocorticoids in GCA?

Yes: Francesco Muratore
No: Peter Villiger
Debate 21

March 8, 2025, 14:30-15:30 (CET)

Transition From Psoriasis to Psoriatic Arthritis: Are We Getting Closer?

Yes: Alen Zabotti
No: Dennis McGonagle

Stay in touch

Subscribe to our newsletter to make sure you never miss a deadline and receive the latest updates in your inbox.
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